| SEC Form 4 |  |
|------------|--|
|------------|--|

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL             |     |  |  |  |  |  |  |  |
|--------------------------|-----|--|--|--|--|--|--|--|
| OMB Number: 3235-028     |     |  |  |  |  |  |  |  |
| Estimated average burden |     |  |  |  |  |  |  |  |
| hours per response:      | 0.5 |  |  |  |  |  |  |  |

| 1. Name and Address of Reporting Person <sup>*</sup><br>Okajima Masatsune |                               |                | 2. Issuer Name and Ticker or Trading Symbol<br><u>MEDICINOVA INC</u> [ MNOV ] | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>Director 10% Owner<br>Conflicer (give title Other (specify  |
|---|-------------------------------|----------------|---|---|
| (Last)<br>4275 EXECUT<br>SUITE 650  | (First) (Middle) CUTIVE DRIVE |                | 3. Date of Earliest Transaction (Month/Day/Year)<br>06/14/2012                | X Oncer (give nue Other (specify<br>below) below)<br>VP and Head of Japanese Office   |
| (Street)<br>LA JOLLA<br>(City)  | CA<br>(State)                 | 92037<br>(Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year)                      | <ul> <li>6. Individual or Joint/Group Filing (Check Applicable Line)</li> <li>X Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting Person</li> </ul> |

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) |      |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and<br>5) |               |       | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--|---|------|---|---|---------------|-------|---|---|---|
|                                 |  |   | Code | v | Amount  | (A) or<br>(D) | Price | Transaction(s)<br>(Instr. 3 and 4)  |   | (1150.4)  |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D) (Instr.<br>3, 4 and 5) |     | of Securities       |                    | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |   |  |
|---|---|--|---|------------------------------|---|--|-----|---------------------|--------------------|---|--|--|--|---|--|
|   |   |  |   | Code                         | v | (A)  | (D) | Date<br>Exercisable | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares   |  |  |   |  |
| Stock<br>Option<br>(Right to<br>Buy)                | \$2.46  | 06/14/2012                                 |   | A                            |   | 63,750   |     | 06/14/2012          | 08/02/2021         | Common<br>Stock                                     | 63,750   | \$0.00   | 63,750 <sup>(1)</sup>  | D |  |

Explanation of Responses:

1. On August 3, 2011, the reporting person was granted an option to purchase 85,000 shares of common stock, subject to the satisfaction of certain performance criteria. On June 14, 2012, the Compensation Committee of the Board determined that certain of the performance criteria had been met, resulting in the vesting of 75% of the option, or 63,750 shares. The remaining 25% of the option did not vest.

## Remarks:

| <u>/s/ Masatsune Okajima</u>     |  |
|----------------------------------|--|
| ** Signature of Reporting Person |  |

04/25/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Instruction 1(b).